Total Wealth Keith Fitz-Gerald’s ET-743

By lougiam, February 18, 2016

Relatively new to the site – was wondering how to submit teasers for research – thought I’d try here, but please point me in the right direction if there’s a preferred route.

Anyone know what company Keith Fitz-Gerald is teasing about on Total Wealth? He talks about about a small biotech company with a monopoly on one of the rarest resources on the planet, called ET-743. Has anyone else heard of this, and know what company he’s referring to?

Thanks,
Lou

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

48
Share your thoughts...

avatar
24 Comment threads
24 Thread replies
0 Followers
 
Most reacted comment
Hottest comment thread
28 Comment authors
james brunoSandy PilonCarlosSunil Gurungwsattler Recent comment authors

This site uses Akismet to reduce spam. Learn how your comment data is processed.

wsattler
Member
πŸ‘27
wsattler

I just listened to Michael Robinson’s half hour presentation on the ultimate cancer drug ET.-743. There is no listed company. NSDQ Listing is anticipated for the second half of 2016. There is private placement prospectus where “round lot units” for $245 per unit
Can be purchased. Robinson guarantees at least six times you money in 2016.
You can get prospectus with purchase of his service for $2000.
Maybe our Gumshoe can find out where to get the prospectus.

Add a Topic
3397
Juan M
Guest
Juan M

Probably is this medicament http://www.yondelis.com/ to the spanish group PHARMA MAR R (PHM.MC) and Janssen. In the spanish wikipedia web about ET_742 you can read “A preparation of trabectedin is marketed under the name d Yondelis, produced by the company PharmaMar Zeltia group.” https://es.wikipedia.org/wiki/Trabectedina
But I canΒ΄t confirm that he talk about this or other firm…
Any other posibility?
Regards

Add a Topic
5916
Add a Topic
5350
Add a Topic
5456
james bruno
Guest
james bruno

this the company its on the spain ex and over the counter symbol phmmf

Greg Garman
Guest
Greg Garman

You can try “med Plus”.

Edward
Guest
Edward

Try Zeltia a Spanish phama.- Trabectedin (also known as ecteinascidin 743. Sold by zeltia n J&J

Add a Topic
5456
Add a Topic
5456
pablo
Guest
pablo

hola NASDAQ cual seria bien el detalle como para comprar quiero decir con que nombre lo busco no entiendo mucho de esto pero me interesa lo que pueda suceder con estas acciones gracias

alex
Guest
alex

I know what the companies name is. Is there a way to get in with just that info or do you need all this special stuff in the prospectus?

modernrock
Irregular
πŸ‘236

Buy it on spanish exchange, there is not private placement or secret shares.

WOLFGANG
Guest

Zeltia is the Spanish Parent. But their pharma involvement is small. I believe
the Zeltia subsidiary PharmaMar USA is the one that is presently selling with a private placement memorandum. They have an office on the East Coast. They have a web site.
I suspect they gave the Money Map People a couple of weeks to peddle the deal.
Wolfgang

Add a Topic
5456
Add a Topic
5456
Add a Topic
5350
Travis Johnson, Stock Gumshoe
Admin
πŸ‘12364

I haven’t looked at the details and don’t know the company or its financial status (or the science, frankly), but would urge anyone interested in a stock to simply buy it on its home exchange if you’re convinced it’s a good buy. If Money Map does have some special private placement, which would be odd and could put them at huge regulatory risk, it’s probably a lousy deal that comes with strings. Companies that have options and valuable assets do not generally try to get new shareholders with promotions like that or deals with overpromisers like Robinson — Sometimes investing… Read more Β»

Add a Topic
5971
Add a Topic
605
Add a Topic
570
modernrock
Irregular
πŸ‘236

There is NOT NOT NOT a private placement.

Bob
Guest
Bob

Wasn’t there a recent reverse merger of the parent company (Zeltia) into the subsidiary (PharmaMar), which is the producer of the anti-cancer drug?

Add a Topic
5456
Add a Topic
5350
canklam
Member
πŸ‘14
canklam

I am a member of Money Morning, and I believe that Keith Fitz-Gerald should give this information out to us, it’s members. If I understand this right, and I put in for 2 units, at a cost of $245 per unit, or $490.00 and add the cost of getting the information at a cost of $2000 , for a total cost of $2490, I would get back 6 times the $490.00 or $2,490 That means I would get back my money, MINUS the fees for buying the stock. So to make money on this, you need to buy more than… Read more Β»

Add a Topic
3415
Add a Topic
906
Add a Topic
1340
MSM
Guest

I found this abstract write up on Trabectedin: Ecteinascidin 743.

I also saw this reference to a new NASDAQ filing a spinoff of PharmaMar from Zeltia. This is related to Yondelis. Johnson & Johnson owns the marketing rights for Yondelis outside Europe and Japan.
Check it out here:
http://www.bloomberg.com/news/articles/2014-03-06/zeltia-said-to-explore-spinoff-of-cancer-unit-pharmamar

Add a Topic
5350
Add a Topic
5456
Add a Topic
1029
MSM
Guest

Meant to include this abstract:
http://www.ncbi.nlm.nih.gov/pubmed/16922593

syfi
Member
πŸ‘2
syfi

Don’t forget the mentioned huge IRS tax break that comes with this. Maybe we need Dr. KSS have a look at this for a better perspective….

Add a Topic
3932
modernrock
Irregular
πŸ‘236

long term capital gains

modernrock
Irregular
πŸ‘236

Forgot the foreign tax credit, Spain gets their fair share and then you get a credit for it against your taxes.

Elsie
Guest
Elsie

When I checked pubmed on published results of ET-743 (other name Trabectedin etc), it is hardly as effective as described in Michael Robinson’s presentation, even for in treatment of various types of sarcoma cancers. For example see http://www.sciencedirect.com/science/article/pii/S095980491400046X

imjake4u
Member
πŸ‘1
imjake4u

Two units would be sufficient for a profit. $490 x 6 = 2940 for a profit of 450 (minus fees). Your math is a little off.

canklam
Member
πŸ‘14
canklam

I must be a little Dyslexic. I saw the 2940 as 2490. Sorry.

Dave
Guest
Dave

Alex, would you care to share that infor with us?

Eric
Member
πŸ‘9
Eric

https://www.pharmamar.com/wp-content/uploads/2015/10/INFORME-SEPTIEMBRE-2015-en.pdf Cash and Debt Cash and cash equivalents plus current and non-current financial assets amounted to 50.3 million euro (36.6 million euro at 2014 year-end). The Group’s total interest-bearing debt (current and non-current) amounted to 109.7 million euro (91.5 million euro at 31 December 2014). Consequently, Group net debt at 30 September 2015 totalled 59.5 million euro (54.9 million euro at 31 December 2014). In the first half of the year, the company began reorganising its debt in order to extend the maturity of bank loans so as to gain flexibility by releasing cash that can be used for R&D.… Read more Β»

Add a Topic
1230
Add a Topic
1230
Add a Topic
1340
Eric
Member
πŸ‘9
Eric

Quite a bit of debt here. Just something to consider. I would wait until NASDAQ listed personally.. It’s down about 50% in the last year.

Eric
Member
πŸ‘9
Eric

They spent a lot on R & D, decent revs. They revolutional products may be able to turn them into a big player. Will watch to become NASDAQ listed.

syfi
Member
πŸ‘2
syfi

Oncology Pipeline: https://www.pharmamar.com/science-and-innovation/oncology-pipeline/

James Hefley
Guest
James Hefley

Link for prospectus:

https://www.pharmamar.com/wp-content/uploads/2015/11/Documento-Equivalente-definitivo-en-2.pdf

Bob
Guest
Bob

Correction: the prospectus you list is simply the filing for merger of the parent company into the subsidiary. It is not an offering prospectus.

Glenn Rosendahl
Guest

I am a medical practitioner. I look at this drug from a different perspective than I have been reading out there in ‘tease-land’ and in Stock Gumshoe. This drug was in major discussion in 2001 [http://www.ncbi.nlm.nih.gov/pubmed/11165136], I read further discussion in 2010 [http://mct.aacrjournals.org/content/9/8/2157.full] and in 2014 [http://www.nature.com/bjc/journal/v111/n4/full/bjc2014149a.html]. It is put up as a chemotherapy of last resort in ‘relapsed platinum-sensitive ovarian cancer’ (which means, so far, is has appeared valuable in the most limited of circumstances, and even that value is questionable. If it is such a wonder drug, how come it is still in technical discussion, and only in… Read more Β»

Add a Topic
5971
Add a Topic
5610
Add a Topic
3397
Travis Johnson, Stock Gumshoe
Admin
πŸ‘12364

That sounds like a good question to me…

Wolfgang
Guest

ET-743 is a new, tweaked version with much better results. It has been approved in Europe for three cancers.
FDA has approved it as a Stage 4 “Last Resort” drug, with a 70% remission rate .
Clinical Trials are underway in the US for at least three more cancers. We non-practicioners
believe FDA approves in tiny steps to protect the cancer industry, since they pay the FDA 2.5 Billion per year. In addition this stuff is expensive and broad approval would hurt the Insurance companies.

Add a Topic
3022
Add a Topic
3022
Add a Topic
3397
Glenn Rosendahl
Guest

Wolfgang, would you please drop in a reference or two that demonstrate your claim that ET-743 is a ‘new tweaked version’. I would expect that any significant alteration (improvement) in the drug would be identified by an altered, different descriptor. Otherwise, how would one clinically tell the difference between the two?

Wolfgang
Guest

This company has been around since 1986. The initial trials were made with an extract from a dime size sea creature. Early names were long Latin names starting with E and T. In Europe trials were conducted in hwith “Yondelis”. Johnson and Johnson is one purveyor of recent versions of ET 743. Latest version is a synthetic, tweaked copy. CEO was interviewed by financial guru Michael Robinson and parts of that interview are shown in the Monemap teaser. This private company sold $110,000,000 of ET 743 and other sea creature formulations. Today is the last day to view that half… Read more Β»

Add a Topic
1251
SoGiAm
Member
πŸ‘11365

PharMar’s PM-184 begins Phase II trial for breast cancer )no position) @Cortellis T.G.I.F. Best2You-Ben

Add a Topic
3359
Add a Topic
3397
Tohotfru
Guest
Tohotfru

If something’s too good to be true…….
That’s how Bernie Madoff got all your money as you cried boo hoo hoo woe is me.
Just saying ….. this guy reminds me of a newer version of bernie

Tohotfru
Guest
Tohotfru

The internet is a glorious and wonderful tool if used correctly and asked the right questions. Here are 3 questions I asked Google and the results will give you every piece of disclosed information out there to give you an educated decision on pharmarmar/zeltia group you ever need to know and this took me 10 minutes of my time. 1) is pharmarmar Mar a good company to invest in? 2) who is pharma Mar owned by? 3) zeltia group annual report? Found out on the last question pharma Mar merged with zeltia group in 2015 and now is the parent… Read more Β»

Add a Topic
5456
Add a Topic
5456
Add a Topic
5456
Eric
Member
πŸ‘9
Eric

I’m keeping an eye on this & wondering if this is such a great opportunity why is it kissing 52 week lows? It trades on the grey marketas PHMMF at a .20 premium to the price on yahoo finance.

Eric
Member
πŸ‘9
Eric

https://www.google.com/finance?q=PHMMF&ei=zLHRVpnXCoaxmAHC0ZHQBA

Txbluebonnet
Guest
Txbluebonnet

I believe the original company, the Spanish one(?) OWNS the copyrights to the PROCESS that synthesizes the particular medication from the original organism from the ocean. The medication has been approved for use in some of the Asian countries as well as the European nations. 2 or 3 trials are currently being conducted in the US. The speculation is that the drugs will be hopefully be approved for use here with expanded use for other cancers. HOWEVER, if the drug tests out very well, do you REALLY think the FDA and the big pharmas will actually present something that will… Read more Β»

Add a Topic
3022
Add a Topic
3397
physiksisphun
Guest
physiksisphun

A bit more to the point: J&J has the rights for distribution and sale in the U.S. So if you’re expecting to cash in on sales in the U.S., you’re talking about the wrong company. Pharmamar licensed the original process (using the sea animals) decades ago from U of Illinois (ca 1986), and I think they more recently licensed the process for synthesizing it from Harvard. I’m pretty sure they don’t own any of the patents (or “copyrights”).

Add a Topic
5350
Tohotfru
Guest
Tohotfru

TX is right…there’s no money in a cure.

Rebecca
Guest

Thanks so much for all your comments,, and perspectives , I can not at this time afford 2 or more lots to break even if all goes well? So will not invest thanks

Miceal
Member
πŸ‘312
Miceal

The following, summarised from Edison research provides an overview of current status as per Edison: PharmaMar has built a pipeline of first-in-class cancer drugs for development with strategic partners. Royalty income from the recent approvals for Yondelis for soft tissue sarcoma in Japan and the US should drive strong profit growth from 2017 onwards. The 420-patient Phase III trial of PM1183 in platinum-resistant ovarian cancer was cleared to continue in February after an interim safety analysis on the first 80 patients. Potential near-term catalysts include Aplidin Ph III data in multiple myeloma (Q116). The oncology portfolio has been validated through… Read more Β»

Add a Topic
5350
Add a Topic
3397
Add a Topic
996
wsattler
Member
πŸ‘27
wsattler

Back in February I bought the US version of Pharmamar with symbol PHMMF.
It tracks the Madrid version . I paid $2.60 and it recently made a new high of $3.50 when on August 2 they started a new Phase 3 Trial fo small cell lung cancer.
The MoneyMap people are still waiting for a NASDAQ listing for PharmaMar.

Add a Topic
5350
Add a Topic
4555
Add a Topic
3397
Sunil Gurung
Guest
Sunil Gurung

I found this company as a PharmaMar after long research, How can we buy shares of this company. That I couldn’t figure out. Can any one suggest

Add a Topic
5350
Carlos
Guest
Carlos

Please explain if I purchase a share of the stock ( PHM.ES ) that trade in Spain Stock Exchange & a share of the stock ( PHMMF ) that trade in USA over the counter before the company’s IPO NASDQ offering.

How does both share of stocks ( PHM.ES & PHMMF ) convert to the share that you will be offering in upcoming IPO NASDQ offering in New York ?

Add a Topic
5971
Add a Topic
5971
Add a Topic
5971
Sandy Pilon
Guest

The company is PharmaMar working in conjunction with Johnson& Johnson Go to https://www.ncbi.nlm.nih.gov/pubmed/16922593 for an in depth explanation of the company.

Add a Topic
5350
james bruno
Guest
james bruno

this stock went down over 1.00 on no news now it seems to be going back up on good news does anyone know if Robinson is still in this position or has he told his base to get out

Add a Topic
5971